Notably, suppression of ATAD3A oligomerization by either heterozygous knockout or pharmacological inhibition in AD mice enhanced MAM integrity and cholesterol metabolism, suppressed APP processing, mitigated synaptic loss, and ultimately reduced AD-associated neuropathology and cognitive deficits. This evidence concerns the gene ATAD3A and Cognitive impairment.